Original news and analysis on international IP policy
By Dugie Standeford for Intellectual Property Watch A groundbreaking agreement between the UK government, major internet service providers (ISPs) and the music and film industries could signal that efforts to engage ISPs in fighting digital copyright piracy are gaining momentum.…
By Monika Ermert for Intellectual Property Watch Harmonisation of copyright regulation in recent years has overly “focussed on securing rightsholders’ ability to benefit from new modes of exploitation and business models” and has primarily served “the interests of copyright exporting…
Monika Ermert pour Intellectual Property Watch Contrairement à ce que les négociateurs européens avaient affirmé au sujet du temps nécessaire pour peaufiner l’Accord commercial anti-contrefaçon (ACAC), les pays semblent à présent prêts à accélérer les négociations. La question de l’ACAC…
By Liza Porteus Viana for Intellectual Property Watch
The United States Patent and Trademark Office is meeting with industry groups and intellectual property experts to determine how to strike just the right balance on industrial design protection in the United States.
In the US, design patents can protect the ornamental appearance of manufactured items such as cars. These differ from utility patents, which provide protection for the innovative, functional aspects of a product as embodied in the structure or operation of the product. Original equipment manufacturers (OEMs) often spend millions, if not billions, of dollars creating unique and distinctive designs for their products, whether they be strollers, mobile phones, household appliances or clothing.
But recent moves by the European Union in loosening patent protection for car repair parts, specifically, has gotten some attention in the United States, as has a legislative bill sponsored by Representative Zoe Lofgren (Democrat, California). So the USPTO wants to round up ideas and opinions on market effects of such actions, particularly when this country has seen an "incremental increase in design applications" being filed - about 5,000 more in 2007 than in 2003.
Por Monika Ermert para Intellectual Property Watch A pesar de las declaraciones anteriores de negociadores europeos que sostenían que se necesitaría más tiempo para realizar las adaptaciones necesarias al planificado Acuerdo Comercial de Lucha contra la Falsificación (ACTA, por su…
Par Wagdy Sawahel pour Intellectual Property Watch Dans une invitation à renforcer la collaboration régionale dans les domaines de l’industrie de la création, du droit d’auteur et des droits connexes, dix-sept ministres africains de l’art et de la culture, ont…
By Tatum Anderson for Intellectual Property Watch
An important court case in the ongoing saga between two of the mobile industry's most influential technology firms begins next week.
The case is a crucial stage in the ongoing disagreement between the two equipment manufacturers - Finnish Nokia and US Qualcomm - that has become increasingly acrimonious over recent years and resulted in numerous patent infringement cases all over the world.
By Dugie Standeford for Intellectual Property Watch In a flurry of intellectual property-related activity, the European Commission this week ordered copyright collecting societies to loosen their stranglehold on cross-border music licensing, proposed extending the term of copyright protection to 95…
By Wagdy Sawahel for Intellectual Property Watch CAIRO – African countries recently approved a plan to set up a parliamentary knowledge network to enhance legislative and institutional capacity for creating science and technology-based legislation including intellectual property rights. But the…
By Liza Porteus Viana for Intellectual Property Watch
When Biotechnology Industry Organization CEO Jim Greenwood meets with members of the United States Congress to talk to them about follow-on biologics, he brings a graphic model of an aspirin and a DVD showing the complex molecules of a biologic drug. He uses these visuals to help explain the differences between traditional chemical drugs and newer, cutting-edge biological ones being used in many breakthrough therapies for cancer, multiple sclerosis, HIV/AIDS, and other diseases.
The differences between traditional chemical drugs and biological ones is the crux of the debate going on in the United States as Congress and the Food and Drug Administration (FDA) try to create a regulatory pathway that gives consumers greater access to cheaper, generic biological drugs, but still spurs innovation and protects innovator patent claims.
"When the legislation was introduced at the beginning of this Congress, most pundits expected that we'd oppose it," said Greenwood, a former House representative from Pennsylvania, told Intellectual Property Watch. "But that was a mistake the pharmaceutical industry made in the '80s - trying to resist the notion you could safely make generics …our view at BIO is that we need to follow the science, and science says you can make follow-on biologics that can be safe and can save the consumer money and therefore we support it."
By Monika Ermert for Intellectual Property Watch Despite earlier statements by European negotiators that the planned Anti-Counterfeiting Trade Agreement (ACTA) would need time for fine-tuning, nations seem to accept a fast track movement now. ACTA has been mentioned as an…
By Wagdy Sawahel for Intellectual Property Watch Seventeen African ministers of arts and culture have officially launched the newly formed Southern and Eastern Africa Copyright Network (Seaconet) in a bid to strengthen regional collaboration and cooperation in the field of…